Antimicrobial resistance (AMR) is linked to rising mortality, widening inequities and a growing operational burden for health systems. The challenge is not defining the threat but ensuring health systems can respond faster than resistance evolves. AMR is a systems problem requiring coordinated strategy rather than periodic infection control initiatives. Three reinforcing pillars define the response: surveillance that detects earlier, stewardship that scales reliably and innovation that expands therapeutic options. Health systems positioned to manage AMR effectively treat it as a data-driven operational discipline supported by governance, accountability and measurable performance across care environments.
Surveillance Must Become Actionable
Surveillance forms the backbone of a credible AMR strategy, yet fragmentation persists across many regions. Constraints include limited laboratory capacity, inconsistent reporting standards and weak integration between clinical care and public health systems. Resistance trends often become visible only after clinical disruption occurs. Standardisation initiatives such as the World Health Organization’s Global Antimicrobial Resistance Surveillance System (GLASS) support harmonised reporting across countries, while national and regional surveillance networks enable structured monitoring of healthcare-associated infections and resistance patterns.
Must Read: EU/EEA Tuberculosis Diagnostics Strategy
Participation in surveillance alone does not ensure impact. Surveillance must be modernised to inform operational decisions and prevention strategies. Earlier detection of resistance trends and actionable reporting are essential. Integration of genomic tools strengthens surveillance capability. Whole-genome sequencing (WGS) enables precise tracking of resistant organisms and transmission pathways, including prediction of drug susceptibility in tuberculosis. Genomic surveillance also distinguishes sporadic infections from clustered transmission, which is critical during outbreaks.
AMR surveillance extends beyond hospitals. Resistance moves through communities, agriculture, pharmaceutical manufacturing, wastewater and food supply systems. Surveillance limited to clinical settings remains reactive. Cross-sector surveillance enables coordinated response and earlier intervention.
Stewardship Embedded in Clinical Workflows
Surveillance alone does not change outcomes without consistent prescribing practices. Antimicrobial stewardship improves clinical outcomes, reduces unnecessary antibiotic exposure and limits resistance pressure. Stewardship interventions reduce infections and colonisation with resistant organisms and Clostridioides difficile.
Implementation within routine clinical care remains the central challenge. Time pressure, diagnostic uncertainty and variation in clinical culture limit consistent adoption. Health data infrastructure enables stewardship principles to translate into reliable practice. Embedding stewardship into electronic health records and decision support systems supports scalability.
Clinical frameworks such as the Four Moments of antibiotic decision-making provide structure, but effectiveness depends on workflow integration. Operational stewardship capabilities include visibility into antibiotic initiation, feedback on prescribing variation, integration of local antibiograms into ordering workflows and structured de-escalation pathways with defined stop dates. Stewardship functions most effectively as system design supported by governance and continuous measurement.
Innovation and Policy to Reopen Therapeutic Options
Surveillance and stewardship reduce resistance pressure but do not eliminate the need for new therapies. The antibiotic development pipeline has slowed due to economic disincentives and regulatory complexity. New incentive models are required to support antibiotic discovery and development.
Innovation extends beyond traditional antibiotics. Bacteriophage therapy targets specific bacteria using viruses. Antimicrobial peptides and other non-traditional approaches expand therapeutic possibilities. AI-enabled drug discovery accelerates early-stage identification of antimicrobial compounds by reducing discovery timelines.
Funding models must reflect AMR’s public-good characteristics. Initiatives such as CARB-X support antimicrobial innovation. AMR is transnational and cross-sector, requiring collaboration across healthcare, agriculture and environmental domains. The World Health Organization’s global action plan provides a coordinated framework supported by national action plans. The One Health perspective links resistance dynamics across human medicine, agriculture and the environment. Restricting antibiotic use in food-producing animals is associated with reduced resistance.
AMR is an operational risk requiring sustained system-level response rather than isolated interventions. Progress depends on surveillance infrastructure capable of earlier detection including genomic tools, stewardship embedded within clinical workflows and innovation supported by coordinated policy and funding. Health systems that align these capabilities with governance and measurement are better positioned to maintain effective treatment options and preserve patient safety as resistance continues to evolve.
Source: Health Data Management
Image Credit: iStock
